-
Something wrong with this record ?
Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis
TC. Assumpção, DM. Mizurini, D. Ma, RQ. Monteiro, S. Ahlstedt, M. Reyes, M. Kotsyfakis, TN. Mather, JF. Andersen, J. Lukszo, JMC. Ribeiro, IMB. Francischetti,
Language English Country Great Britain
Document type Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
Grant support
ZIA AI000810
NIAID NIH HHS - United States
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
- MeSH
- Arterial Occlusive Diseases chemically induced pathology prevention & control MeSH
- Chlorides toxicity MeSH
- Fibrinolysis drug effects MeSH
- Ticks metabolism MeSH
- Mice MeSH
- Noxae toxicity MeSH
- Plasminogen metabolism MeSH
- Salivary Proteins and Peptides pharmacology MeSH
- Saliva metabolism MeSH
- Tissue Plasminogen Activator metabolism MeSH
- Thrombosis chemically induced pathology prevention & control MeSH
- Ferric Compounds toxicity MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Intramural MeSH
Tick saliva is a rich source of modulators of vascular biology. We have characterized Ixonnexin, a member of the "Basic-tail" family of salivary proteins from the tick Ixodes scapularis. Ixonnexin is a 104 residues (11.8 KDa), non-enzymatic basic protein which contains 3 disulfide bonds and a C-terminal rich in lysine. It is homologous to SALP14, a tick salivary FXa anticoagulant. Ixonnexin was produced by ligation of synthesized fragments (51-104) and (1-50) followed by folding. Ixonnexin, like SALP14, interacts with FXa. Notably, Ixonnexin also modulates fibrinolysis in vitro by a unique salivary mechanism. Accordingly, it accelerates plasminogen activation by tissue-type plasminogen activator (t-PA) with Km 100 nM; however, it does not affect urokinase-mediated fibrinolysis. Additionally, lysine analogue ε-aminocaproic acid inhibits Ixonnexin-mediated plasmin generation implying that lysine-binding sites of Kringle domain(s) of plasminogen or t-PA are involved in this process. Moreover, surface plasmon resonance experiments shows that Ixonnexin binds t-PA, and plasminogen (KD 10 nM), but not urokinase. These results imply that Ixonnexin promotes fibrinolysis by supporting the interaction of plasminogen with t-PA through formation of an enzymatically productive ternary complex. Finally, in vivo experiments demonstrates that Ixonnexin inhibits FeCl3-induced thrombosis in mice. Ixonnexin emerges as novel modulator of fibrinolysis which may also affect parasite-vector-host interactions.
Institute of Medical Biochemistry Federal University of Rio de Janeiro Rio de Janeiro Brazil
Institute of Parasitology Biology Center Czech Academy of Sciences České Budějovice Czech Republic
Laboratory of Malaria and Vector Research NIAID National Institutes of Health Bethesda USA
Rhode Island Center for Vector Borne Disease University of Rhode Island Kingston Rhode Island USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045525
- 003
- CZ-PrNML
- 005
- 20200113082330.0
- 007
- ta
- 008
- 200109s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-018-22780-1 $2 doi
- 035 __
- $a (PubMed)29555911
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Assumpção, Teresa C $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
- 245 10
- $a Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis / $c TC. Assumpção, DM. Mizurini, D. Ma, RQ. Monteiro, S. Ahlstedt, M. Reyes, M. Kotsyfakis, TN. Mather, JF. Andersen, J. Lukszo, JMC. Ribeiro, IMB. Francischetti,
- 520 9_
- $a Tick saliva is a rich source of modulators of vascular biology. We have characterized Ixonnexin, a member of the "Basic-tail" family of salivary proteins from the tick Ixodes scapularis. Ixonnexin is a 104 residues (11.8 KDa), non-enzymatic basic protein which contains 3 disulfide bonds and a C-terminal rich in lysine. It is homologous to SALP14, a tick salivary FXa anticoagulant. Ixonnexin was produced by ligation of synthesized fragments (51-104) and (1-50) followed by folding. Ixonnexin, like SALP14, interacts with FXa. Notably, Ixonnexin also modulates fibrinolysis in vitro by a unique salivary mechanism. Accordingly, it accelerates plasminogen activation by tissue-type plasminogen activator (t-PA) with Km 100 nM; however, it does not affect urokinase-mediated fibrinolysis. Additionally, lysine analogue ε-aminocaproic acid inhibits Ixonnexin-mediated plasmin generation implying that lysine-binding sites of Kringle domain(s) of plasminogen or t-PA are involved in this process. Moreover, surface plasmon resonance experiments shows that Ixonnexin binds t-PA, and plasminogen (KD 10 nM), but not urokinase. These results imply that Ixonnexin promotes fibrinolysis by supporting the interaction of plasminogen with t-PA through formation of an enzymatically productive ternary complex. Finally, in vivo experiments demonstrates that Ixonnexin inhibits FeCl3-induced thrombosis in mice. Ixonnexin emerges as novel modulator of fibrinolysis which may also affect parasite-vector-host interactions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a arteriální okluzní nemoci $x chemicky indukované $x patologie $x prevence a kontrola $7 D001157
- 650 _2
- $a chloridy $x toxicita $7 D002712
- 650 _2
- $a železité sloučeniny $x toxicita $7 D005290
- 650 _2
- $a fibrinolýza $x účinky léků $7 D005342
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a noxy $x toxicita $7 D009676
- 650 _2
- $a plazminogen $x metabolismus $7 D010958
- 650 _2
- $a sliny $x metabolismus $7 D012463
- 650 _2
- $a slinné proteiny a peptidy $x farmakologie $7 D012471
- 650 _2
- $a trombóza $x chemicky indukované $x patologie $x prevence a kontrola $7 D013927
- 650 _2
- $a klíšťata $x metabolismus $7 D013987
- 650 _2
- $a tkáňový aktivátor plazminogenu $x metabolismus $7 D010959
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mizurini, Daniella M $u Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- 700 1_
- $a Ma, Dongying $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
- 700 1_
- $a Monteiro, Robson Q $u Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- 700 1_
- $a Ahlstedt, Sydney $u Department of Pathology, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
- 700 1_
- $a Reyes, Morayma $u Department of Pathology, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
- 700 1_
- $a Kotsyfakis, Michail $u Institute of Parasitology, Biology Center, Czech Academy of Sciences, České Budějovice, Czech Republic.
- 700 1_
- $a Mather, Thomas N $u Rhode Island Center for Vector-Borne Disease, University of Rhode Island, Kingston, Rhode Island, USA.
- 700 1_
- $a Andersen, John F $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
- 700 1_
- $a Lukszo, Jan $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
- 700 1_
- $a Ribeiro, José M C $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
- 700 1_
- $a Francischetti, Ivo M B $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA. ivofrancischetti@gmail.com.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 8, č. 1 (2018), s. 4806
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29555911 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113082702 $b ABA008
- 999 __
- $a ok $b bmc $g 1483793 $s 1084198
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 8 $c 1 $d 4806 $e 20180319 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a ZIA AI000810 $p NIAID NIH HHS $2 United States
- LZP __
- $a Pubmed-20200109